Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Licenses Technology for Mouse Analysis

Premium

Exelixis of San Francisco said it licensed genetic technology to enable advanced analysis in the laboratory mouse.

The licensed technology, which was originally developed by William Dove of the Wisconsin Alumni Research Foundation, elucidates gene function and will possibly allow Exelixis to identify key disease genes or drug targets that would be difficult to identify with alternative mouse technologies, the company said.

Using the technology, a researcher can assign a gene to a particular biochemical or disease-related signaling pathway and establish the consequence of modifying its activity with respect to a desired therapeutic outcome, Exelixis said.

Filed under

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.